Browse IL27RA

Summary
SymbolIL27RA
Nameinterleukin 27 receptor, alpha
Aliases WSX-1; TCCR; WSX1; zcytor1; IL-27R; T-cell cytokine receptor type 1; IL-27RA; IL27R; IL-27 receptor subunit ......
Chromosomal Location19p13.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Membrane; Single-pass type I membrane protein.
Domain PF00041 Fibronectin type III domain
Function

Receptor for IL27. Requires IL6ST/gp130 to mediate signal transduction in response to IL27. This signaling system acts through STAT3 and STAT1. Involved in the regulation of Th1-type immune responses. Also appears to be involved in innate defense mechanisms.

> Gene Ontology
 
Biological Process GO:0000018 regulation of DNA recombination
GO:0001819 positive regulation of cytokine production
GO:0002200 somatic diversification of immune receptors
GO:0002204 somatic recombination of immunoglobulin genes involved in immune response
GO:0002208 somatic diversification of immunoglobulins involved in immune response
GO:0002250 adaptive immune response
GO:0002263 cell activation involved in immune response
GO:0002285 lymphocyte activation involved in immune response
GO:0002312 B cell activation involved in immune response
GO:0002366 leukocyte activation involved in immune response
GO:0002377 immunoglobulin production
GO:0002381 immunoglobulin production involved in immunoglobulin mediated immune response
GO:0002440 production of molecular mediator of immune response
GO:0002443 leukocyte mediated immunity
GO:0002449 lymphocyte mediated immunity
GO:0002460 adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002562 somatic diversification of immune receptors via germline recombination within a single locus
GO:0002637 regulation of immunoglobulin production
GO:0002683 negative regulation of immune system process
GO:0002694 regulation of leukocyte activation
GO:0002697 regulation of immune effector process
GO:0002700 regulation of production of molecular mediator of immune response
GO:0002703 regulation of leukocyte mediated immunity
GO:0002706 regulation of lymphocyte mediated immunity
GO:0002712 regulation of B cell mediated immunity
GO:0002819 regulation of adaptive immune response
GO:0002821 positive regulation of adaptive immune response
GO:0002822 regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002824 positive regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002825 regulation of T-helper 1 type immune response
GO:0002827 positive regulation of T-helper 1 type immune response
GO:0002828 regulation of type 2 immune response
GO:0002829 negative regulation of type 2 immune response
GO:0002889 regulation of immunoglobulin mediated immune response
GO:0006310 DNA recombination
GO:0016064 immunoglobulin mediated immune response
GO:0016444 somatic cell DNA recombination
GO:0016445 somatic diversification of immunoglobulins
GO:0016447 somatic recombination of immunoglobulin gene segments
GO:0019724 B cell mediated immunity
GO:0032609 interferon-gamma production
GO:0032649 regulation of interferon-gamma production
GO:0032729 positive regulation of interferon-gamma production
GO:0042088 T-helper 1 type immune response
GO:0042092 type 2 immune response
GO:0042113 B cell activation
GO:0042742 defense response to bacterium
GO:0045190 isotype switching
GO:0045191 regulation of isotype switching
GO:0048291 isotype switching to IgG isotypes
GO:0048302 regulation of isotype switching to IgG isotypes
GO:0050777 negative regulation of immune response
GO:0050830 defense response to Gram-positive bacterium
GO:0050864 regulation of B cell activation
GO:0050865 regulation of cell activation
GO:0051052 regulation of DNA metabolic process
GO:0051249 regulation of lymphocyte activation
GO:0070106 interleukin-27-mediated signaling pathway
GO:0098542 defense response to other organism
Molecular Function GO:0004896 cytokine receptor activity
GO:0030368 interleukin-17 receptor activity
GO:0045509 interleukin-27 receptor activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04630 Jak-STAT signaling pathway
Reactome R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-6788467: IL-6-type cytokine receptor ligand interactions
R-HSA-168256: Immune System
R-HSA-6783589: Interleukin-6 family signaling
R-HSA-449147: Signaling by Interleukins
Summary
SymbolIL27RA
Nameinterleukin 27 receptor, alpha
Aliases WSX-1; TCCR; WSX1; zcytor1; IL-27R; T-cell cytokine receptor type 1; IL-27RA; IL27R; IL-27 receptor subunit ......
Chromosomal Location19p13.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between IL27RA and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between IL27RA and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
19549909Breast Carcinoma; Head and Neck Squamous Cell CarcinomaPromote immunityExpression of exogenous WSX1 in epithelial tumor cells suppresses tumorigenicity in vitro and inhibits tumor growth in vivo. Different from the role of WSX1 in immune cells, the antitumor activity of WSX1 in epithelial tumor cells is independent of IL-27 signaling but is mainly dependent on natural killer (NK) cell surveillance. Deficiency of either the IL-27 subunit EBV-induced gene 3 or the IL-27 receptor WSX1 in the host animals had no effect on tumor growth inhibition induced by WSX1 expression in tumor cells. Expression of WSX1 in epithelial tumor cells enhances NK cell cytolytic activity against tumor cells, whereas the absence of functional NK cells impairs the WSX1-mediated inhibition of epithelial tumor growth. Our results reveal an IL-27-independent function of WSX1: sensitizing NK cell-mediated antitumor surveillance via a NKG2D-dependent mechanism.
Summary
SymbolIL27RA
Nameinterleukin 27 receptor, alpha
Aliases WSX-1; TCCR; WSX1; zcytor1; IL-27R; T-cell cytokine receptor type 1; IL-27RA; IL27R; IL-27 receptor subunit ......
Chromosomal Location19p13.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of IL27RA in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolIL27RA
Nameinterleukin 27 receptor, alpha
Aliases WSX-1; TCCR; WSX1; zcytor1; IL-27R; T-cell cytokine receptor type 1; IL-27RA; IL27R; IL-27 receptor subunit ......
Chromosomal Location19p13.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of IL27RA in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.4520.355
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.8750.556
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.1380.898
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.4110.347
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.6650.615
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.0920.957
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.5280.308
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.6420.579
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.4360.725
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.7850.51
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.0630.549
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.130.432
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of IL27RA in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.15.91.21
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103033.3-33.30.231
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 414250250.222
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.45.51.90.66
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 01407.1-7.11
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.45.12.30.647
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 382707.4-7.40.169
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221307.7-7.70.371
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161407.1-7.10.467
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolIL27RA
Nameinterleukin 27 receptor, alpha
Aliases WSX-1; TCCR; WSX1; zcytor1; IL-27R; T-cell cytokine receptor type 1; IL-27RA; IL27R; IL-27 receptor subunit ......
Chromosomal Location19p13.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of IL27RA. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolIL27RA
Nameinterleukin 27 receptor, alpha
Aliases WSX-1; TCCR; WSX1; zcytor1; IL-27R; T-cell cytokine receptor type 1; IL-27RA; IL27R; IL-27 receptor subunit ......
Chromosomal Location19p13.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of IL27RA. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by IL27RA.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolIL27RA
Nameinterleukin 27 receptor, alpha
Aliases WSX-1; TCCR; WSX1; zcytor1; IL-27R; T-cell cytokine receptor type 1; IL-27RA; IL27R; IL-27 receptor subunit ......
Chromosomal Location19p13.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of IL27RA. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolIL27RA
Nameinterleukin 27 receptor, alpha
Aliases WSX-1; TCCR; WSX1; zcytor1; IL-27R; T-cell cytokine receptor type 1; IL-27RA; IL27R; IL-27 receptor subunit ......
Chromosomal Location19p13.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of IL27RA expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolIL27RA
Nameinterleukin 27 receptor, alpha
Aliases WSX-1; TCCR; WSX1; zcytor1; IL-27R; T-cell cytokine receptor type 1; IL-27RA; IL27R; IL-27 receptor subunit ......
Chromosomal Location19p13.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between IL27RA and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolIL27RA
Nameinterleukin 27 receptor, alpha
Aliases WSX-1; TCCR; WSX1; zcytor1; IL-27R; T-cell cytokine receptor type 1; IL-27RA; IL27R; IL-27 receptor subunit ......
Chromosomal Location19p13.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting IL27RA collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.